Hyponatremia, heart failure, and the role of Tolvaptan

Postgraduate Medicine

Volumn 124, Issue 2, 2012, Pages 29-39

  O'Connell, John B ^a   Alemayehu, Addis ^b  

^a Heart Failure Consultants   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Heart failure; Hyponatremia; Tolvaptan; Vasopressin antagonists; Volume status

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ARGIPRESSIN; CONIVAPTAN; DEMECLOCYCLINE; DIURETIC AGENT; FUROSEMIDE; LITHIUM; LOOP DIURETIC AGENT; NEUROLEPTIC AGENT; NICOTINE; NITROGEN; PLACEBO; PROTON PUMP INHIBITOR; SULFONYLUREA DERIVATIVE; TOLVAPTAN; UREA; URIC ACID;

ARTICLE; BRAIN DAMAGE; BRAIN HERNIA; BRAIN STEM HERNIATION; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL PONTINE MYELINOLYSIS; COGNITIVE DEFECT; COMA; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DILUTIONAL HYPONATREMIA; DISORIENTATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EUVOLEMIC HYPONATREMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPERVOLEMIA; HYPERVOLEMIC HYPONATREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; HYPOVOLEMIA; HYPOVOLEMIC HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; KIDNEY FAILURE; LETHARGY; LIVER FAILURE; LOADING DRUG DOSE; MORTALITY; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; ORTHOSTATIC HYPOTENSION; PHOTOSENSITIVITY; PLASMA OSMOLALITY; PROGNOSIS; RESPIRATORY ARREST; RESTLESSNESS; SEIZURE; SIDE EFFECT; SODIUM RESTRICTION; TASTE; THIRST; UNPLEASANT TASTE; UREMIA; URINARY FREQUENCY; VOMITING; WATER RETENTION; XEROSTOMIA;

BENZAZEPINES; DIAGNOSIS, DIFFERENTIAL; HEART FAILURE; HUMANS; HYPONATREMIA; PROGNOSIS; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME;

EID: 84858842068     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.03.2534     Document Type: Article

References (61)

1. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003;37(11):1694-1702.
2. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064-2072.
3. Waikar SS, Mount DB, Curham GC. Mortality and hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009; 122(9):857-865.
4. Shorr AF, Tabak YP, Johannes RS, et al. Burden of sodium abnormalities in patients hospitalized for heart failure. Congest Heart Fail. 2011;17(1):1-7.
5. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28(8):980-988.
6. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007;167(18):1998-2005.
7. Barsheshet A, Shotan A, Cohen E, et al; HFSIS Steering Committee and Investigators. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail. 2010;12(8): 833-840.
8. Goldberg A, Hammerman H, Petcherski S, etal. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med. 2006;166(7):781-786.
9. Singla I, Zahid M, Good CB, et al. Effect of hyponatremia (, 135mEq/L) on outcome in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2007;100(3):406-408.
10. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to hospital with congestive heart failure. Arch Intern Med. 1996;156(16):1814-1820.
11. Kearney MT, Fox KAA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40(10):1801-1808.
12. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure. Derivation and validation of a clinical model. JAMA. 2003;290(19):2581-2587.
13. Chen MC, Chang HW, Cheng CI, Chen YH, Chai HT. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology. 2003;100(3):136-142.
14. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156(4):662-673.
15. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342(21):1581-1589.
16. Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005;25(3):240-249.
17. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11A):S1-S21.
18. Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006;73(suppl 3): S24-S33.
19. LeJemtel TH, Serrano C. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. Int J Cardiol. 2007;120(1):1-9.
20. Goldsmith SR. Treating hyponatremia in heart failure. Curr Cardiol Rep. 2006;8:204-210.
21. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42(5):790-806.
22. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144-153.
23. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With the Guidelines Program. Circ Cardiovasc Qual Outcomes. 2010;3(1):25-32.
24. O'Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010;55(9):872-878.
25. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424-1433.
26. Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177(12):1364-1369.
27. Dimopoulos K, Diller G-P, Petraco R, et al. Hyponatremia: a strong predictor of mortality in adults with congenital heart disease. Eur Heart J. 2010;31(5):595-601.
28. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hos- pital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294-302.
29. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians, et al. ACC/ AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2005;112:e154-e235.
30. Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37(3):149-155.
31. Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med. 2006;119(suppl 1): S12-S16.
32. Heart Failure Society of America; Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1-e194.
33. Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: evaluation and management. Hosp Pract. 2010;38(1):89-96.
34. Schrier RW, Bansal S. Diagnosis and management of hyponatremia in acute illness. Curr Opin Crit Care. 2008;14(6):627-634.
35. Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29(3):282-299.
36. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: provid- ing treatment and avoiding harm. Cleve Clin J Med. 2010;77(10): 715-726.
37. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4(8):1522-1530. Hyponatremia, Heart Failure, and Tolvaptan
38. Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry. 2004;75(suppl 3):iii22-iii28.
39. Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail. 2010;16(5):419-431.
40. Licata G, Pasquale PD, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145(3):459-466.
41. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail. 2000;2(3):305-313.
42. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391-e479.
43. Vaprisol (conivaptan hydrochloride) injection, for intravenous use [package insert]. Deerfield, IL: Astellas Pharma US, Inc; February 2011.
44. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447-457.
45. Ghali JK, Koren MJ, Taylor JR, etal. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab.2006;91(6):2145-2152.
46. Annane D, Decaux G, Smith N; Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337(1):28-36.
47. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral doses in rats. J Pharmacol Exp Ther. 1998;287(3):860-867.
48. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin- 2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290(2):F273-F278.
49. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963-1971.
50. Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17(12):973-981.
51. Schrier RW, Gross P, Gheorghiade M, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099-2112.
52. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec F. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011;164(5):725-732.
53. Samsca™ (tolvaptan) tablets for oral use [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc; May 2009.
54. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97(7):1064-1067.
55. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. The EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332-1343.
56. Konstam MA, Gheorghiade M, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST Outcome Trial. JAMA. 2007;297(12):1319-1331.
57. Pang PS, Konstam MA, Krasa HB, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30(18):2233-2240.
58. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J Am Coll Cardiol. 2008;52(19):1540-1545.
59. Cyr PL, Slawsky KA, Olchanski N, et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health-Syst Pharm. 2011;68(4): 328-333.
60. Tribouilloy C, Buiciuc O, Rusinaru D, et al. Long-term outcome after a first episode of heart failure. A prospective 7-year study. Int J Cardiol. 2010;140(3):309-314.
61. Bettari L, Fiuzat M, Shaw LK, et al. Hyponatremia and long-term outcomes in heart failure. Poster presented at: 60th Annual Scientific Session of the American College of Cardiology; April 2-5, 2011; New Orleans, LA.